Andrea Posted August 18, 2004 Share Posted August 18, 2004 Here I was thinking I knew it all about LC and ready to open up my own advice line (Just kidding, but fun to think back to Nov when I freaked out over low platelets. Isn't it common knowledge that is nothign to worry about? Wait, no, it is not b/c I worried too way back when. Heehee). Low and behold, the beautiful Connie alerted me to the fact that there is a sister drug to Iressa. Who knew? Not me Does anyone happen to know the name? I searched actually last week to see if there were any Iressa alternatives and found nothing. I also searched for a new drug also I heard was coming out soon which is similar to Iressa, but I thought it was called Travocera and I could not find that either. Thanks Quote Link to comment Share on other sites More sharing options...
Elaine Posted August 18, 2004 Share Posted August 18, 2004 Connie gave you the right answer! It may still be in trials--David A was on it and I think Cheryl. Taraveca has not yet been FDA approved. They are drugs that act similar to Iressa. Don't know if they are sisters or cousins or sons or daughters! elaine Quote Link to comment Share on other sites More sharing options...
Andrea Posted August 18, 2004 Author Share Posted August 18, 2004 Traveca! BIngo. I was doign Travocera and got zilch. Thanks! Quote Link to comment Share on other sites More sharing options...
niececola Posted August 18, 2004 Share Posted August 18, 2004 Hi Andrea, The drug name is actually Tarceva. It is not yet available, but a special program is starting up this summer. I have attached the article below. Because we know it will take the FDA several months to review this data after it is submitted, Genentech and OSI are working with the FDA and patient advocates to implement an open-label Tarceva access trial for patients with recurrent or refractory non-small cell lung cancer for whom standard chemotherapy has failed. Patients in this access trial will receive Tarceva as a monotherapy. It is our hope that the trial will be available to patients in the U.S. by mid-summer of 2004. For more information, please call 888-662-6728. We will strive to keep patients and physicians updated on the availability of Tarceva as we move forward. For information on Genentech's clinical trials, please call our Trial Information Support Line at 888-662-6728. For more information on lung cancer, call the Alliance for Lung Cancer Advocacy, Support and Education at 800-298-2436, the American Cancer Society at 800-ACS-2345, CancerCare at 212-712-8400 or the NCI Cancer Information Service at 800-4-CANCER. For information about ongoing lung cancer research, visit www.clinicaltrials.gov, or ask your physician about treatment options. Not sure if your mom is available for the program, but I hope this helps! denise Quote Link to comment Share on other sites More sharing options...
john Posted August 18, 2004 Share Posted August 18, 2004 There are also Tyrosine-kinase inhibitors (like Iressa/Tacveca): CI-1033 GW2016 PKI-116 CP358 monoclonal antibodies: ABX-EGF CI-1033 erbitux hR3 EMD72000 Quote Link to comment Share on other sites More sharing options...
Fay A. Posted August 19, 2004 Share Posted August 19, 2004 New one under investigation in clinical trials for lung cancer is Lapatinib, which does a double attack on two different Epidermal Growth Factor Receptors. I guess this one would be a first cousin twice removed. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.